<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00773825</url>
  </required_header>
  <id_info>
    <org_study_id>P040440</org_study_id>
    <nct_id>NCT00773825</nct_id>
  </id_info>
  <brief_title>Genomic Imprinting and Assisted Reproductive Technologies</brief_title>
  <acronym>EPIGEN</acronym>
  <official_title>Assessment of the Risk of Imprinting Defects in Children Born Following Assisted Reproductive Technologies (ART)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Genomic imprinting, referring to an epigenetic marking resulting in monoallelic gene&#xD;
      expression, plays a critical role in development. Recently, various imprinting diseases were&#xD;
      reported in animals (Large Offspring syndrome (LOS)) and humans (Beckwith-Wiedemann syndrome&#xD;
      (BWS) and Angelman syndrome (AS)) born after ART. In all cases, an imprinting defect was&#xD;
      involved (loss of methylation at ICR2 in BWS, at SNRPN in AS and at IGF2R DMR2 in LOS). These&#xD;
      data suggest that ART procedures may impair the establishment or the maintenance (following&#xD;
      fertilization) of methylation marks at maternally imprinted loci. In view of these data, the&#xD;
      aim of this study is to determine if children born following ART exhibit an increased risk of&#xD;
      imprinting defects. If the answer is yes, the second objective is to identify the problematic&#xD;
      step in the ART procedure and thus to suppress or modify this step.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Methodology: assessment of the methylation status at 9 different imprinted loci (using&#xD;
      Southern blot and methyl-specific quantitative PCR) in 3 groups of patients: 150 children&#xD;
      naturally conceived, 150 children conceived after ovarian stimulation but with in vivo&#xD;
      fertilization, and 150 children conceived after ovarian stimulation and in VITRO&#xD;
      fertilization. These analyses will be performed on cord blood. Fragments of placental tissue&#xD;
      will also be collected for further analyses. Patients will be selected in maternity hospitals&#xD;
      associated with ART departments ( ANTOINE BECLERE HOSPITAL, Cochin HOSPITAL, Saint-Vincent de&#xD;
      Paul HOSPITAL, Jean VERDIER HOSPITAL, Tenon HOSPITAL and Dijon Hospital).&#xD;
&#xD;
      This work is also a unique opportunity to establish a DNA, RNA and tissue collection allowing&#xD;
      further investigation regarding other epigenetic modifications than DNA methylation, not only&#xD;
      at imprinted loci, but also in other genomic regions regulated by epigenetic modifications.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of the methylation status at 9 imprinted loci in cord blood collected just after birth.</measure>
    <time_frame>At the birth</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of other epigenetic marks (histone modifications) at imprinted loci and at non imprinted but epigenetically regulated loci.</measure>
    <time_frame>At the birth</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">542</enrollment>
  <condition>Natural Pregnancy</condition>
  <condition>Pregnancy, Ovarian</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Pregnancy after ICSI or IVF</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>Pregnancy after ovarian stimulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <description>natural pregnancy</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood (serum, ADN) and placenta samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Women followed in a participating ART departments&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Mother :&#xD;
&#xD;
          -  Age: 26 to 40 at conception&#xD;
&#xD;
          -  Single foetus pregnancy&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Affiliation to French health benefits&#xD;
&#xD;
          -  Absence of maternal pathology&#xD;
&#xD;
          -  Normal foetal karyotype (if available)&#xD;
&#xD;
          -  Known procedure of ovarian stimulation&#xD;
&#xD;
          -  ART procedure without sperm or oocyte donation&#xD;
&#xD;
          -  ART in a participating ART departments&#xD;
&#xD;
          -  Delivery in a participating hospital&#xD;
&#xD;
        Father&#xD;
&#xD;
          -  Age : 18 to 50 at conception&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Abnormal foetal karyotype (if available)&#xD;
&#xD;
          -  Delivery before 35 weeks of amenorrhea&#xD;
&#xD;
          -  Delivery in not participating hospital&#xD;
&#xD;
          -  Delivery complication leading to the absence of sample collection&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>26 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yves Le BOUC, PUPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Trousseau Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Gicquel C, El-Osta A, Le Bouc Y. Epigenetic regulation and fetal programming. Best Pract Res Clin Endocrinol Metab. 2008 Feb;22(1):1-16. doi: 10.1016/j.beem.2007.07.009. Review.</citation>
    <PMID>18279777</PMID>
  </reference>
  <reference>
    <citation>Rossignol S, Steunou V, Chalas C, Kerjean A, Rigolet M, Viegas-Pequignot E, Jouannet P, Le Bouc Y, Gicquel C. The epigenetic imprinting defect of patients with Beckwith-Wiedemann syndrome born after assisted reproductive technology is not restricted to the 11p15 region. J Med Genet. 2006 Dec;43(12):902-7. Epub 2006 Jul 6.</citation>
    <PMID>16825435</PMID>
  </reference>
  <reference>
    <citation>Gicquel C, Gaston V, Mandelbaum J, Siffroi JP, Flahault A, Le Bouc Y. In vitro fertilization may increase the risk of Beckwith-Wiedemann syndrome related to the abnormal imprinting of the KCN1OT gene. Am J Hum Genet. 2003 May;72(5):1338-41.</citation>
    <PMID>12772698</PMID>
  </reference>
  <reference>
    <citation>Gaston V, Le Bouc Y, Soupre V, Burglen L, Donadieu J, Oro H, Audry G, Vazquez MP, Gicquel C. Analysis of the methylation status of the KCNQ1OT and H19 genes in leukocyte DNA for the diagnosis and prognosis of Beckwith-Wiedemann syndrome. Eur J Hum Genet. 2001 Jun;9(6):409-18.</citation>
    <PMID>11436121</PMID>
  </reference>
  <verification_date>June 2015</verification_date>
  <study_first_submitted>October 15, 2008</study_first_submitted>
  <study_first_submitted_qc>October 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2008</study_first_posted>
  <last_update_submitted>June 17, 2015</last_update_submitted>
  <last_update_submitted_qc>June 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Genomic imprinting</keyword>
  <keyword>Reproductive techniques, assisted</keyword>
  <keyword>Beckwith-Wiedemann syndrome</keyword>
  <keyword>Angelman syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregnancy, Ovarian</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

